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Abstract 
Objectives: Time within therapeutic INR range (TTR) predicts benefits/risk of 
warfarin therapy. Identification of individual- and centre-related factors that influence 
TTR, and addressing them to improve anticoagulation control, are important. This 
study examined the impact of individual and centre-related factors upon long-term 
anticoagulation control in atrial fibrillation patients in seven UK-based monitoring 
services.  
 
Methods:  Data between 2000 and 2014 on 25,270 patients (equating to 203,220 
patient years) [18,120 (71.7%) in general practice, 2,348 (9.3%) in hospital-based 
clinics and 4,802 (19.0%) in domiciliary service] were analysed. 
 
Results: TTR increased with increasing age, peaking around 77% at 70-75 years, 
and then declined, was lower in females than males, and in dependent home-
monitored patients than those attending clinic (P<0.0001). TTR, number of dose 
changes and INR monitoring events, and the probability of TTR≤ 65%, differed 
across the centres (P<0.0001).  
 
Conclusions: Although all the participating centres ostensively followed a standard 
dosing algorithm, our results indicate that variations in practice do occur between 
different monitoring sites. We suggest feedback on TTR for individual monitoring 
sites gauged against the average values reported by others would empower the 
individual centres to improve quality outcomes of anticoagulation therapy by 
identifying and adjusting contributory factors within their management system.   
 
Key words: warfarin, atrial fibrillation, anticoagulation, stroke, TTR 
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Introduction 
 
Trial data of patients with atrial fibrillation (AF) taking warfarin indicate that quality of 
warfarin use, as measured by average time in the standard target range (TTR) of 
2.0-3.0 influences both risk of major bleeding and thromboembolic events (1). Similar 
benefits in terms of preventing stroke or systemic embolism have been noted both in 
patients treated with non-vitamin K antagonist oral anticoagulants (NOACs) and 
those treated with warfarin with high TTR (2), with no differences between the 
treatments in rates of thromboembolic or thrombotic events where, in warfarin 
treated patients, mean TTR was 70% (3). As a result of these findings interpolated 
TTR (4) has become a standard measure of quality of warfarin management.  
Unfortunately many vitamin K antagonist (VKA) treated patients do not achieve a 
TTR of >70%, with a meta-analysis of published data suggesting that patients spend 
an average of 61%, 25% and 14% of their time within, above and below range, 
respectively (5). This is important as patients with an individual TTR of less than 
70%, or high INR variability, have an increased rate of major bleeding or 
thromboembolism (6); those with a TTR of > 70% have a 79% reduced risk of stroke 
compared with those with <30% TTR, and mortality rates are significantly lower in 
those with a TTR >70% than those not achieving this (7). 57% of thrombotic events 
and 42% of haemorrhage events occur at an INR of <2.0 and >3.0 respectively (5). 
Factors influencing TTR are both individual based (iTTR) and centre based (cTTR), 
with iTTR significantly predicting risk of major haemorrhage, ischaemic stroke and 
all-cause mortality, and cTTR being a weak predictor of all-cause mortality (8). 
Identification of the influences upon these outcomes is important to ascertain which 
ones are modifiable and improvable.  
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Patient factors known to predict poor INR control include age less than 60 years, 
female sex and having more than 2 co-morbidities, factors which have been included 
in the SAME-TT2R2 score aimed at aiding decision making between a NOAC and a 
VKA (9), heart failure (10) and severe chronic kidney disease (11). In an earlier 
longitudinal study of anticoagulation control we demonstrated a biphasic relationship 
with age, TTR peaking at 67 years, being poorer in females than in males, and in 
patients monitored at home due to dependency and immobility than in those 
attending monitoring clinic (12). 
 
VKA monitoring setting influences TTR with patients managed in anticoagulation 
clinics and with adherence to a warfarin dosing algorithm having better control and 
outcomes than those managed in community settings (8, 13, 14).  Thus, for example, 
patients in North America spend significantly less time in the therapeutic range than 
those in Europe, where results are best in Sweden, then the United Kingdom (UK) 
(5), both of which have a similar anticoagulant management system. In the United 
States (US) however, only about one third of patients have access to an 
anticoagulant clinic (15), and other strategies which can improve TTR for some 
patients such as self-monitoring are less used (16). 
 
We set out to investigate the impact of age, gender and differences between 
management systems (hospital, general practice and domiciliary) on anticoagulation 
control in seven UK-based centres to determine to what extent our earlier 
observations of age-related effects upon %TTR were replicable elsewhere, and to 
examine any differences in centre-based TTRs which might be indicative of system-
based differences in management which could potentially be addressed to enhance 
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the quality of anticoagulation control, as many of the patient factors influencing TTR 
are fixed and may not be easily amenable to change by targeted interventions. 
 
Patients, materials and Methods 
 
The study involved audit of anonymised electronic data held by 7 centres across the 
UK using the DAWN computer dosing programme (version 6.10, Milnthorpe, 
Cumbria, UK) (17), and as such, the study was deemed not to require ethical 
approval.  Patient inclusion criteria were to have AF, paroxysmal, persistent or 
valvular, anticoagulated for stroke and systemic embolism prevention and with a 
target INR of 2.0-3.0. Only these patients were selected in order to reduce bias 
related to different indications or target INR ranges. After excluding the data for the 
first six months of warfarin therapy, only those patients aged 40 years or older who 
were monitored for 5 consecutive years or more, and had 4 or more yearly INR 
measurements, without a change in monitoring setting were included in the final 
analysis. Data mining was facilitated by DAWN which allowed extraction of 
information on individual patients and their anticoagulation management setting, 
between 2000 and 2014, including a DAWN coded patient ID (in order to preserve 
patient anonymity for data analysis), age, sex, indication for anticoagulant therapy, 
target INR range, date commencing warfarin treatment and starting dose, duration of 
warfarin therapy, mean annual warfarin dose, annual number of INR monitoring 
events and warfarin dose changes. Data for mobile patients who attended either 
hospital or general practice based clinics, and for patients housebound by physical 
dependency or limited mobility who were monitored through the domiciliary service 
whereby trained staff visited them at their place of residence for venous or point of 
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care INR checks, were audited.  Information on co-morbidities and concurrent 
therapy, major bleeding or thromboembolism, was not available.  
 
Statistical Analysis 
The mean of the individual variables, including % time within, below and above 
therapeutic INR range (TTR) established using the linear extrapolation (4), number 
of INR determinations and dose changes, and average warfarin dose was 
determined according to each year of age collectively for all centres and for each 
centre individually. 
 
Examination of the data showed that INR control was less good in the youngest and 
oldest patients. As a result a polynomial model with age was fitted to the means to 
describe this effect and the way the covariates of setting and gender affected this 
model was examined. The number of INR measurements and the number of warfarin 
dose changes were transformed into their square roots to approach normality. 
 
Since some data had a polynomial pattern, for later analysis quadratic, cubic, quartic 
and linear regression models were applied to examine the effect of age for all the 
variables tested.  
 
Weighted analysis was used in all statistical calculations because of the large 
variation in sample sizes across age groups. Individual observations were also 
analysed using random effects to take account of the longitudinal nature of the data. 
This form of analysis was more complex due to the non-normal nature of the data. 
The same conclusions were obtained and so the analysis of means is presented 
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here as the interpretation of the analysis is much more straightforward. The 
probability of a TTR ≤65% according to age was determined using binary logistic 
regression analysis. Quartic regression models were used to examine the effect of 
age on gender, monitoring centre, and monitoring setting. Data were analysed using 
Minitab statistical software (version 17.0) and R statistical package. Data are 
presented as mean±SD unless stated otherwise. 
 
Results 
Data belonging to 72,441 AF patients (equating to 384,977 patient years) 
anticoagulated with warfarin for stroke and systemic embolism prevention with INR 
target of 2.0-3.0 in 7 different centres across 6 different regions in the UK were 
extracted from DAWN electronic database. A total of 25,270 patients (203,220 
patient years) with 2,308,043 INR determinations and 664,717 warfarin dose 
changes were available for data analysis. For centres 2, 3, 6 and 7, patients were 
recorded as being monitored either at ‘hospital’,’ GP’, or ‘home’. For centres 1 and 4, 
patients were monitored at either ‘home’ or ‘GP’, and for centre 5 at ‘GP’ only. The 
clinic monitoring system description and the number of patients monitored and their 
mean age at each of the individual centres according to setting are presented in 
Table 1 and Table 2, respectively.   
 
%TTR, time spent above and below target INR range were significantly associated 
with age (P<0.0001), (Fig 1). The %TTR increased with increasing age, peaked to 
about 77% at 70-75 years of age, and declined with increasing age thereafter. The 
time spent above target INR range was greater in older age, whereas the time below 
target INR range was greater in younger age. For the whole study population age 
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accounted for 95%, 87%, and 91% of the variability in mean TTR, time spent above 
and below target INR range, respectively.      
 
Warfarin dose requirement fell with increasing age (P<0.0001, quartic regression), 
with age accounting for 99.7% of the variability in dose requirement. Hospital and GP 
monitored patients were prescribed a significantly higher mean warfarin dose than 
those monitored at home for most ages, the reverse being true for age less than 55 
(P<0.0001).  For the whole population both the mean number of dose changes (as 
square root) (P<0.0001, R2=96%, quartic regression) and the mean number of INR 
monitoring events (as square root) (P<0.0001, R2=95%, cubic regression) were 
significantly related to age (Fig 2).   
 
There was a highly significant difference in both the number of INR measurements 
(square root; P<0.0001, R2=90%, cubic regression) and warfarin dose changes 
(P<0.0001, R2=93%, quartic regression) between the 7 study centres (Table 3).    
TTR was found to be highly significantly different between the seven centres 
(P<0.0001, R2=93%, quartic regression). Centre 5 had the highest TTR and 
probability of having a TTR ≥ 65% and centre 6 the lowest (P<0.001), particularly for 
patients aged over 80 years. Percentage time above (P<0.0001, R2=91%, cubic 
regression) and below target INR range (P<0.0001, R2=82%, quartic regression) was 
highly significantly different between the seven centres; centre 5 had the lowest 
%time above target INR range, and centre 3 the highest. Centres 5 and 7 had the 
two lowest %time below target INR range; centre 6 had the highest, contributed to by 
warfarin doses which were significantly lower than those recorded at the other study 
centres (P<0.0001, R2=99%, quartic regression); (Fig 3).  
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In females the mean TTR was marginally lower (by 1.12%; P<0.0001), and both the 
mean %time below (0.57%, P<0.0001) and above target INR range (0.53%, 
P<0.0001) were marginally higher compared to males. Female patients had a 
marginally higher number of recorded INR checks (P<0.0001). Warfarin doses for 
females were significantly lower than those for males (P<0.0001), and they had more   
dose changes (P<0.0001) than their male counterparts. In spite of this, females had 
a slightly higher probability of having a TTR ≤65% (P<0.0001, quartic regression) 
compared to males, with centre 6 having the highest probability and centre 5 the 
lowest (P<0.0001, quartic regression).  
     
The TTR of patients monitored at hospital and GP settings exceeded that of those 
monitored at home by 3.7% whereas, for the %time above and below target INR 
range, patients monitored at home exceeded those monitored at hospital and GP by 
1.6% and 2.1%, respectively (P<0.0001), but with a non-interacting effect with age.   
Patients monitored at home had a greater frequency of INR checks and warfarin 
dose changes (by 0.24 and 0.26 of squared root values, respectively) but,(with the 
exclusion of centres 5 and 6 as centre 5 has no home-monitored system in place 
and there was a small number of home-monitored patients at centre 6), 
nevertheless, had a markedly greater probability of having a TTR ≤65% compared to 
hospital and GP monitored patients; ~10% greater across most ages. 
 
Discussion 
 
In this study we were able to follow-up longitudinally 25,270 patients (amounting to 
203,220 patient years of observation) across 7 different centres and establish that 
there is a consistent pattern of the effects of age and gender and dependency upon 
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TTR, it peaking at around 70-75 years, being lower in females than in males and in 
individuals requiring home monitoring than those attending clinic, whilst there are 
considerable differences between the centres in quality of anticoagulant control 
achieved. Achieving good anticoagulation control is important to optimising 
outcomes in AF patients taking warfarin, with risks of death, MI, major bleeding, 
stroke or systemic embolism being related to anticoagulation control (18). Using data 
from the ARISTOTLE, ROCKET AF and RELY trials of use of apixaban, rivaroxaban 
and dabigatran respectively, it has been estimated that, among non-valvular AF 
patients, each 10% increase in TTR in warfarin treated patients correlates with a 
0.32% per year decrease in stroke/ systemic embolism rate, but it has no effect on 
major bleeding (19).  
 
As noted in our previous single centre longitudinal study (12), we have confirmed a 
consistent curvilinear relationship between TTR and age across all the three 
monitoring settings (hospital, GP and domiciliary) in the 7 studied centres at 6 
different geographical locations across the UK, with TTR peaking at age 71. There 
was an inverse relationship between the number of INR checks and warfarin dose 
changes and age. 
 
This curvilinear pattern was found for percentage of time both above and below 
range. The probability of having a TTR ≤ 65% increased over the age of 70 years, 
and control across centres was, as in our previous study (12), consistently worse in 
females than in males and in those monitored at home rather than clinic who had 
lower TTRs and spent more time both above and below their target range, in spite of 
greater frequency of INR checks and warfarin dose changes. Anticoagulated female 
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AF patients show a slightly higher rate of ischaemic stroke than male patients (20), 
even after adjusting for TTR (21), suggesting the potential  of a higher net clinical 
benefit of anticoagulant treatment in females, which is not being achieved. The 
greater risk of ischaemic stroke in women, in part related to females spending more 
time outside and below the therapeutic range than men (9, 22), suggests that they 
might benefit from a more aggressive VKA management, or anticoagulation with a 
NOAC, as these drugs have similar efficacy and bleeding risk in women and men 
(23).  
 
The variability of cTTR is remarkable: a meta-analysis reported a range from 40% to 
78% in US-based primary studies (24) and even in randomised controlled trials 
variability ranged from 44% to 77% (25). This is important as the benefit from the 
VKA oral anticoagulants is dependent upon TTR. In AF patients a 10% increase in 
time out of the therapeutic range is associated with an increase in the odds ratio of 
ischaemic stroke of 1.10, P=0.006 (26), and a population-average model predicted 
that a minimum TTR of 58% would be needed to be confident that patients would 
benefit from treatment (1). NOACs show a greater relative reduction in major 
bleeding, mainly driven by a reduction in haemorrhagic stroke compared to warfarin 
therapy when cTTR is <66% whereas the benefits of NOACs over warfarin become 
less apparent when cTTR is ≥66% (27). As warfarin will continue to be used for 
many AF patients including those with rheumatic valvular disease, prosthetic heart 
valves or those with severe kidney disease, it is important to identify features of 
management which achieve excellence in anticoagulant control for sharing and 
adoption by currently less successful anticoagulation monitoring centres as 
achieving even a small percentage improvement in TTR would be of benefit to a 
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large absolute number, given the estimated prevalence of AF in the general 
population of approximately 1%; 2.2 million people in the U.S. and 4.5 million in the 
European Union (28).  
 
Variation in dose adjustment practice between each centre has been associated with 
cTTR, as well as differences in mean target INR levels (29). In our study we 
controlled for the latter by selecting data only from patients with a target range of 2.0-
3.0. Other influences are participation in external assessment of therapy quality (30). 
Internal quality check was performed daily and external quality assurance 
undertaken monthly through National External Quality Assessment Service 
(NEQAS), Sheffield, UK at all the participating anticoagulation centres.  
 
Important influences upon cTTR are that patients managed in a community setting 
have poorer control of anticoagulation when compared to those managed in an 
anticoagulant clinic or a RCT setting (5). Dose adjustments by clinicians, based upon 
experience, tend to under-dose patients whereas adherence to warfarin dosing 
algorithms is effective in improving anticoagulation control (31, 32). In the RELY 
study the degree of adherence accounted for 87% of the variation between 
participating centres and 55% of the between-country variation in TTR (25). Each 
10% increase in the consistent use of dosing algorithm by centre independently 
predicted a 6.12 % increase in TTR and an 8% decrease in the rate of the composite 
clinical outcome (25). Varying degrees of non-adherence to clinical guidelines is 
expected; in one study of USA veterans, none of the 5 sites studied were particularly 
adherent, with consistent patterns of concordant and discordant management in 
terms of dose changes and follow-up intervals being noted (33). Although all the 
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participating centres in our study were ostensively following a standard warfarin 
dosing algorithm, variation in dose adjustment practice across the 7 centres must 
account for some of the observed differences in the study results between centres. 
As systems employing algorithm-based dosing and promoting adherence to them 
could improve clinical outcomes on a global scale, feedback to centres to improve 
patient outcomes by practising in a more guideline concordant manner is 
recommended. Anticoagulation management can be effectively carried out by a 
range of staff members; indeed there is strong evidence that community 
management utilising computer assisted dose adjustment can improve when led by 
pharmacists rather than primary care general practitioners; TTR improving from 
71.4% to 84.1% in one New Zealand based study in spite of no increase in point of 
care INR testing (34). The 80% adherence to the algorithm by pharmacists 
compared to the 70% adherence by doctors was the most important factor 
influencing TTR rather than the specific details of the algorithm. Poorer control 
achieved by doctors compared to pharmacists (TTR 67.4% vs. 75.1%) in another 
study was related to poorer adherence to computer dosing recommendations by 
doctors, with doctors over-riding the algorithm up to 50% of the time when INR was 
below range and tending to under-dose patients, mistakenly believing their own dose 
adjustments were better than the computer programme which had been developed 
using large amounts of patient data (35). Although this perhaps reflects inherent 
concern about the risk of bleeding in poorly controlled patients it will have achieved 
poorer outcomes as a meta-analysis has shown that a 6.9% improvement in TTR 
may reduce major haemorrhage by one event per hundred patient years of treatment 
(36). Centre 6 in our study, which used the lowest doses and had the highest %TTR 
below range and the highest probability of TTR <65%, with comparable mean 
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number of INR monitoring events and dose changes per patient per year to other 
centres (Table 2), had a larger number of individuals making dosing decisions, 
implicating these factors in poorer anticoagulation control. Dosage advice was not 
through a small number of anticoagulant clinic employed pharmacists, nurses or 
biomedical scientists, but was spread among anticoagulant nurses, practice nurses 
and community pharmacists, reducing the consistency of advice given. For centres 5 
and 7, where TTRs were highest, dosing decisions were by anticoagulant nurses 
supported by consultant haematologist or pharmacists. That patients in our cohorts 
were more likely to be below therapeutic INR range and at increased risk of 
thrombosis, as compared to being above the range and at increased risk of bleeding, 
is consistent with pooled analysis of atrial fibrillation studies performed worldwide (5). 
 
Anticoagulation control (TTR) could be improved if staff, whatever their grade, 
exhibited closer adherence to a rigorous protocol, including contacting non-attenders 
as part of their management process. Whilst feedback of a report contrasting their 
cTTR with the average cTTR of other participants may lead to centres taking steps to 
improving their quality, none of our centres was regularly provided with such 
feedback. We suggest that correcting this might be helpful, both to the centre to 
improve anticoagulation control overall and also to give each patient and his or her 
clinician  knowledge of the individual’s TTR over the previous 6 month period of VKA 
therapy to facilitate ongoing informed decision making about the choice of most 
appropriate oral anticoagulant. As whilst nearly 60 % of AF patients on warfarin 
therapy with a TTR ≥70% will maintain this over the next 6 months, for a substantial 
minority TTR will deteriorate; the UK National Institute for Health and Care 
Excellence (NICE) recommends reassessment of anticoagulation for people with a 
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TTR <65% over a maintenance period of at least 6 months (37), and indeed for all 
patients this is important, particularly as patient features have been shown to be poor 
predictors of TTR variability (10).  
 
Whilst INR monitoring intervals and to a lesser extent quality of laboratory INR 
measurement explained about 63.5 % of the total TTR variability among Italian 
Federation of Anticoagulant Clinics (30), we noted more frequent testing and dosing 
changes in older and home-monitored patients who nevertheless had a lower %TTR. 
This suggests that poorer anticoagulation control is related to patient factors such as 
dependency which cannot be completely adjusted for by monitoring and dosing 
decisions.  
 
Limitations are that the study relied on self-reported centre characteristics to 
evaluate their association with centre TTR and this may have introduced information 
bias. Also, we did not measure variations in warfarin adjustment practice between 
centres, which is known to account for considerable cTTR variation and occurs even 
in the study situation (25) where mean percentage of algorithm-consistent warfarin 
dose changes ranged from only 55% in east Asia to 68% in north Europe and shows 
a strong positive association between the use of algorithm dose adjustments and 
TTR. Furthermore, we were unable to assess the extent to which differences in 
levels of co-morbidities and concurrent drug therapy were contributing to differences 
noted between centres, as data on these covariates were unavailable through the 
DAWN programme. This is regrettable as, although confounders are not fully 
elucidated, patient-level characteristics are known to contribute to variability in TTR. 
Of the 42 variables noted to have some influence upon TTR, the 6 clinical variables 
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of pneumonia, renal dysfunction, prior bleeding, hospitalisation, pain medication and 
antibiotic use were particular confounders, but lack of a dedicated anticoagulation 
service with a structured approach to warfarin management was found to be the 
strongest predictor of poor TTR (38). In contrast, whilst comorbidities, medications, 
hospitalisations and ethnicity were shown in a study of 100 Veterans’ Health 
Administration sites to account for 13.3% of the variability in TTR, site-level variability 
explained only 2.9% (39).  
 
In conclusion, the results of this study of 7 UK monitoring centres are consistent with 
those of our previous study in 1 centre (12) in demonstrating that anticoagulation 
control shows a biphasic relationship with age, and is influenced by gender and 
dependency. More importantly in terms of potential for modification, it demonstrates 
differences in anticoagulation control between centres related to variations in 
practice. Feeding back TTR information to individual monitoring sites through peer 
review, such as, in the UK, the NEQAS for blood coagulation, the international 
External Quality Assessment (EQA) programme which provides assessment, 
education and support for centres performing tests of haemostasis and thrombosis 
through expert help, publications and scientific meetings, or through national training 
or clinical governance bodies under umbrella organisations such as, in the UK, the 
Royal College of Pathologists, so that they can gauge their performance against that 
of other services, has the potential to empower individual centres to identify and 
adjust contributory factors within their system, including adherence to algorithmic 
dosing protocol, with the aim of improving the delivery and quality outcomes of oral 
anticoagulation with warfarin.  
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Table 1: System description for all participating centres 
 
 INR testing Dosage Advice Notes
Centre 1 
 
Point of care using Roche 
Coaguchek pro devices 
Biomedical 
scientists or 
nurses
Highest INR measurements
Highest dose changes 
Centre 2 Real time INR using 
capillary method on KC1 
(Hart biological 
machines/reagents/thromb
oplastin) 
Anticoagulant 
nurse 
practitioner 
Education Programme 
Centre 3 
 
Real time capillary method 
Some self-monitoring  
Biomedical 
scientists, 
nurses, clinical 
pharmacists, 
pharmacy 
technicians  
Greatest time above range
Centre 4 
 
Self-monitoring 
(Coaguchek Roche) 
Centre 5: 
 
Venous bloods-posted 
dose advice 100 patients 
self-monitor – telephoned 
dose advice (Roche 
Coaguchek) 
Anticoagulant 
nurses 
Consultant 
Haematologist 
Highest TTR 
Lowest time above range 
Lowest time below range 
Lowest TTR probability ≤65% 
Centre 6: 
 
Capillary generated INR 
using thrombotrak 
coagulometers (Hart 
biological 
reagents/thromboplastin) 
or Roche Coaguchek Pro 
INR monitor 
Some self-monitoring 
Domiciliary service 
Venous INR: 
Community service: Roche 
Coaguchek Pro 
Anticoagulant 
nurses  
Practice nurses 
Community 
pharmacist 
Lowest TTR 
Highest time below range   
Lowest doses prescribed 
Highest TTR probability ≤65% 
Centre 7: 
 
Capillary INR method on 
KCI machines except for 
domiciliary patients who 
used venous INR 
(Instrument Laboratories 
machine and reagents) IL 
(UK)Ltd 
Pharmacist Education Programme 
Lowest time below range 
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  Table 2: Number of patients monitored at each centre, and age (mean±SD) 
according to setting and gender 
 
    Category   
Centre   Domiciliary GP Hospital Total 
Ce
nt
re
 1
 Males 292 997   1,289 
Females 367 614   981 
Total 659 1,611   2,270 
Ce
nt
re
 2
 Males 697 2,715 536 3,948 
Females 909 1,968 327 3,204 
Total 1,606 4,683 863 7,152 
Ce
nt
re
 3
 Males 429 2,084 58 2,571 
Females 567 1,343 63 1,973 
Total 996 3,427 121 4,544 
Ce
nt
re
 4
 Males 363 2,184   2,547 
Females 505 1,331   1,836 
Total 868 3,515   4,383 
Ce
n
tre
 
5 Males   1,794   1,794 
Females   1,258   1,258 
Total   3,052   3,052 
Ce
nt
re
 6
 Males 5 430 476 911 
Females 8 257 397 662 
Total 13 687 873 1,573 
Ce
nt
re
 
7 Males 255 623 299 1,177 
Females 360 322 186 868 
Total 615 945 485 2,045 
To
ta
l 
Males 2,041 10,827 1,369 14,237 
Age    71 ± 9 
Females 2,716 7,093 973 10,782 
Age    75 ± 8 
Total 4,757 17,920 2,342 25,019 
 Age 77 ± 7 71 ± 9 72 ± 10  
N.B. Information about sex was not available for 251 patients  
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Table 3: Mean number of INR checks and warfarin dose changes per patient per 
year in the individual centres  
Centre  Setting 
Total 
number 
of 
patients 
Total 
number 
of 
patients 
years 
Mean 
INR/patient
/year 
Mean 
INR/patient 
/year  
95% CI 
Mean dose 
change/ 
patient/year 
Mean dose 
change/ 
patient/ year  
95%CI 
1 
Home 696 5,971 14.6* (14.3, 14.9) 4.9* (4.7, 5.1) 
GP 1,747 14,831 12.3* (12.1, 12.4) 3.5* (3.4, 3.6) 
Total 2,443 20,802 12.9 (12.7, 13.1) 3.9 (3.8, 4.0) 
2 
Home 1,608 12,456 12.7 (12.5, 12.9) 3.4 (3.3, 3.5) 
GP 4,695 36,161 10.9 (10.8, 11.0) 2.4 (2.3, 2.4) 
Hospital 864 6,492 11.4 (11.2, 11.7) 2.6 (2.5, 2.7) 
Total 7,167 55,109 11.3 (11.3, 11.4) 2.6 (2.6, 2.7) 
3 
Home 1,002 8,198 11.1 (10.9, 11.3) 3.3 (3.2, 3.4) 
GP 3,443 29,587 10.4 (10.3, 10.5) 2.7 (2.6, 2.7) 
Hospital 125 846 11.7 (11.1, 12.3) 3.3 (2.9, 3.6) 
Total 4,570 38,631 10.6 (10.5, 10.7) 2.8 (2.8, 2.9) 
4 
Home 868 7,369 13.4 (13.1, 13.7) 4.5 (4.4, 4.7) 
GP 3,532 29,405 11.0 (10.9, 11.1) 3.0 (2.9, 3.1) 
Total 4,400 36,774 11.5 (11.3, 11.6) 3.3 (3.2, 3.3) 
5 GP 3,065 24,207 11.2 (11.2, 11.3) 3.0 (3.0, 3.1) 
6 
Home 13 88 11.0 (9.7, 12.5) 3.4 (2.7, 4.1) 
GP 693 4,771 9.6 (9.4, 9.9) 2.4 (2.3, 2.6) 
Hospital 874 6,350 12.1ǂ (11.8, 12.5) 3.7ǂ (3.5, 3.9) 
Total 1,580 11,209 11.0 (10.8, 11.2) 3.1 (3.0, 3.2) 
7 
Home 615 4,929 11.9 (11.7, 12.2) 3.3 (3.2, 3.4) 
GP 945 7,799 10.3 (10.2, 10.5) 2.3 (2.3, 2.4) 
Hospital 485 3,760 11.1 (10.8, 11.4) 2.5 (2.3, 2.7) 
Total 2,045 16,488 11.0 (10.9, 11.1) 2.7 (2.6, 2.7) 
Total 
Home 4,802 39,011 12.6 (12.5, 12.7) 3.8 (3.7, 3.8) 
GP 18,120 146,761 10.8 (10.8, 10.9) 2.9 (2.8, 2.9) 
Hospital 2,348 17,448 11.6 (11.5, 11.8) 3.0 (2.9, 3.1) 
Total 25,270 203,220 11.2 (11.2, 11.3) 3.0 (3.0, 3.1) 
N.B. INR checks and warfarin dose changes (both square root) in Centre 1 had 
significantly the highest recorded number (P<0.0001) whereas for other centres 
recordings were fairly similar.  GP and home setting in Centre 1 had significantly 
greater number of INR checks and warfarin dose changes per patient per year in 
comparison to respective settings in the other centres (*P<0.001).  Hospital setting in 
Centre 6 carried out significantly higher number of INR checks and number of dose 
changes per patient per year compared to hospital settings in centres 2 and  7 
(ǂP<0.01). 
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Figure Legends 
Figure 1: Percentage time spent (a) within target INR range, (b) above target range, 
and (c) below target range, for the whole study population with 95% confidence limits 
(dashed lines). 
Figure 2: Square root of number of INR monitoring events (a) and square root of 
number of warfarin dose changes (b) for the whole study population with 95%  
confidence limits (dashed lines). 
Figure 3: Percentage time spent (a) within target INR range, (b) above target range, 
and (c) below target range according to centre. (black=centre 1, red=centre 2, 
green=centre 3, dark blue=centre 4, light blue =centre 5, purple=centre 6, yellow= 
centre 7) 
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